Thursday, 6 March 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 06 March 2025
News

Deal shakes up cholesterol market

Posted 4 March 2024 AM

A new cholesterol drug is on the way to Australia and New Zealand with CSL Seqirus signing a distribution agreement with US based Esperion Therapeutics.

The deal covers both of Esperion's marketed drugs, Nexletol and Nexlizet. Both include bempedoic acid as an active ingredient, and Nexlizet includes ezetimibe. CSL will handle the commercialisation of the drugs, including TGA approval, PBAC and funding processes, and marketing. Esperion will cover product supply.

To see the whole article, please login

Popular

Deal shakes up cholesterol market
March PBS listings climb to 12
$10M Novartis drug faces threat
MD: What we've been waiting for
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (33)

Clinical & Medical, R&D (14)

Other (13)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home